157 related articles for article (PubMed ID: 28187492)
1. Are Evidence Standards Different for Genomic- vs. Clinical-Based Precision Medicine? A Quantitative Analysis of Individualized Warfarin Therapy.
Dhanda DS; Guzauskas GF; Carlson JJ; Basu A; Veenstra DL
Clin Pharmacol Ther; 2017 Nov; 102(5):805-814. PubMed ID: 28187492
[TBL] [Abstract][Full Text] [Related]
2. Personalized medicine: potential, barriers and contemporary issues.
Sorich MJ; McKinnon RA
Curr Drug Metab; 2012 Sep; 13(7):1000-6. PubMed ID: 22591350
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of pharmacogenetics-guided dosing of warfarin: a systematic review and meta-analysis.
Tang Q; Zou H; Guo C; Liu Z
Int J Cardiol; 2014 Aug; 175(3):587-91. PubMed ID: 25005340
[No Abstract] [Full Text] [Related]
4. The Value of Evidence in the Decision-Making Process for Reimbursement of Pharmacogenetic Dosing of Warfarin.
Janzic A; Locatelli I; Kos M
Am J Cardiovasc Drugs; 2017 Oct; 17(5):399-408. PubMed ID: 28528365
[TBL] [Abstract][Full Text] [Related]
5. Study of warfarin utilization in hospitalized patients: analysis of possible drug interactions.
Guidoni CM; Camargo HP; Obreli-Neto PR; Girotto E; Pereira LR
Int J Clin Pharm; 2016 Oct; 38(5):1048-51. PubMed ID: 27365092
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetics-based warfarin dosing algorithm decreases time to stable anticoagulation and the risk of major hemorrhage: an updated meta-analysis of randomized controlled trials.
Wang ZQ; Zhang R; Zhang PP; Liu XH; Sun J; Wang J; Feng XF; Lu QF; Li YG
J Cardiovasc Pharmacol; 2015 Apr; 65(4):364-70. PubMed ID: 25551322
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenomic Biomarkers: an FDA Perspective on Utilization in Biological Product Labeling.
Schuck RN; Grillo JA
AAPS J; 2016 May; 18(3):573-7. PubMed ID: 26912182
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenomics Implementation: Considerations for Selecting a Reference Laboratory.
Vo TT; Bell GC; Owusu Obeng A; Hicks JK; Dunnenberger HM
Pharmacotherapy; 2017 Sep; 37(9):1014-1022. PubMed ID: 28699700
[TBL] [Abstract][Full Text] [Related]
9. Genotype-guided vs clinical dosing of warfarin and its analogues: meta-analysis of randomized clinical trials.
Stergiopoulos K; Brown DL
JAMA Intern Med; 2014 Aug; 174(8):1330-8. PubMed ID: 24935087
[TBL] [Abstract][Full Text] [Related]
10. Using pharmacogenetics in real time to guide warfarin initiation: a clinician update.
Carlquist JF; Anderson JL
Circulation; 2011 Dec; 124(23):2554-9. PubMed ID: 22144632
[No Abstract] [Full Text] [Related]
11. Pharmacogenomics and warfarin therapy.
Ndegwa S
Issues Emerg Health Technol; 2007 Oct; (104):1-8. PubMed ID: 17912794
[TBL] [Abstract][Full Text] [Related]
12. Effect of Genotype-Guided Warfarin Dosing on Clinical Events and Anticoagulation Control Among Patients Undergoing Hip or Knee Arthroplasty: The GIFT Randomized Clinical Trial.
Gage BF; Bass AR; Lin H; Woller SC; Stevens SM; Al-Hammadi N; Li J; Rodríguez T; Miller JP; McMillin GA; Pendleton RC; Jaffer AK; King CR; Whipple BD; Porche-Sorbet R; Napoli L; Merritt K; Thompson AM; Hyun G; Anderson JL; Hollomon W; Barrack RL; Nunley RM; Moskowitz G; Dávila-Román V; Eby CS
JAMA; 2017 Sep; 318(12):1115-1124. PubMed ID: 28973620
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenomic genotypes define genetic ancestry in patients and enable population-specific genomic implementation.
Hernandez W; Danahey K; Pei X; Yeo KJ; Leung E; Volchenboum SL; Ratain MJ; Meltzer DO; Stranger BE; Perera MA; O'Donnell PH
Pharmacogenomics J; 2020 Feb; 20(1):126-135. PubMed ID: 31506565
[TBL] [Abstract][Full Text] [Related]
14. [Companion Diagnostics for Thrombotic Disease].
Masuda Y; Matsuno K; Shimizu C
Rinsho Byori; 2015 Nov; 63(11):1316-22. PubMed ID: 26995878
[TBL] [Abstract][Full Text] [Related]
15. Commentary: Should Pharmacogenomic Evidence Be Considered in Clinical Decision Making? Focus on Select Cardiovascular Drugs.
Bottorff MB; Bright DR; Kisor DF
Pharmacotherapy; 2017 Sep; 37(9):1005-1013. PubMed ID: 28654154
[TBL] [Abstract][Full Text] [Related]
16. Meta-analysis of efficacy and safety of genotype-guided pharmacogenetic dosing of warfarin.
Xu H; Xie X; Wang B; Chen Y; Meng T; Ma S; Wang F
Int J Cardiol; 2014 Dec; 177(2):654-7. PubMed ID: 25449474
[No Abstract] [Full Text] [Related]
17. [Long-term drug interaction of warfarin with amiodarone].
Hirmerová J; Suchý D; Mádr T
Cas Lek Cesk; 2003 Jan; 142(1):39-42. PubMed ID: 12693297
[TBL] [Abstract][Full Text] [Related]
18. Warfarin pharmacogenomics: a big step forward for individualized medicine: enlightened dosing of warfarin.
Elias DJ; Topol EJ
Eur J Hum Genet; 2008 May; 16(5):532-4. PubMed ID: 18301451
[No Abstract] [Full Text] [Related]
19. Comparison of the Guidelines of the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group.
Bank PCD; Caudle KE; Swen JJ; Gammal RS; Whirl-Carrillo M; Klein TE; Relling MV; Guchelaar HJ
Clin Pharmacol Ther; 2018 Apr; 103(4):599-618. PubMed ID: 28994452
[TBL] [Abstract][Full Text] [Related]
20. Building individualized medicine: prevention of adverse reactions to warfarin therapy.
Krynetskiy E; McDonnell P
J Pharmacol Exp Ther; 2007 Aug; 322(2):427-34. PubMed ID: 17496169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
